tbuckley/cabot-search huggingface dataset:
Neoadjuvant chemotherapy for resectable colorectal cancer liver metastases: Impact on magnitude of liver resection and survival
Authors: T. Gruenberger, B. Schuell, G. Kornek, W. Scheithauer
Journal: Journal of Clinical Oncology (2004)

3598 Background: Curative liver resection remains the best treatment option for colorectal liver metastases (CRCLM). Overall survival is still limited due to high recurrence rates. Adjuvant chemotherapy was ineffective in reducing recurrence, therefore neoadjuvant treatment was explored. Methods: During the last two years 50 patients were treated with 6 cycles of neoadjuvant chemotherapy prior to liver resection for CRCLM. Chemotherapy consisted of Oxaliplatin/5-FU/LV according to FOLFOX4 regimen or Oxaliplatin (130mg/m2 d1) and Xeloda (2000mg/m2 d1–7) q14 over a 3 month period. Primary endpoint of these early results were side effects, radiologic and tumor marker response (CEA, CA 19–9), extend of liver resection and perioperative morbidity/mortality. Results: Grad III and IV side effects were seldom recorded in this 3 months regime and consisted of PNP III in 16%, diarrhea III and IV in 12%, nausea III in 8%; hematologic side effects grade III and IV were neutropenia in 2%, thrombocytopenia in in 6% and anemia in 2%. The achieved response rates were 2 complete responses, 33 partial responses, 11 stable diseases and 4 progressions; leading to an ORR of 70 % and a progression under treatment of 8 %. None of the progredient patients became inoperable after CTX. Tumor marker response correlated with radiologic response, 15% of the responding patients obtained a normalization of their tumor marker. The extent of the liver resection could be substantially reduced in responding patients. The perioperative mortality was 0% and the morbidity was 4% (1 bile leak, 1 biloma). At the time of this analysis 48% of the patients are alive without recurrence, 34% have recurrence and 18% died after tumor recurrence. Conclusions: Oxaliplatin based chemotherapy demonstrates a high response rate given preoperatively without increasing the perioperative morbidity. No patient demonstrated with nonresectable disease after CTX. The extend of the intended liver resection was considerably reduced in responders. Survival outcome measurements appear promising and further exploration of preoperative CTX is highly recommended. No significant financial relationships to disclose.
Evaluation of outcomes before and after electronic medical record (EMR) and computerized physician order entry (CPOE) system implementation in an outpatient oncology setting
Authors: C. A. Harshberger, B. Brockstein, G. Carro, W. Jiang, W. Spath, J. Lawton
Journal: Journal of Clinical Oncology (2007)

17058 Background: Computerized physician order entry (CPOE) in electronic medical records (EMR) has been recognized as an important tool in optimal health care provision that can reduce errors and improve safety. The objective of this study is to describe documentation completeness and user satisfaction of medical charts before and after outpatient oncology EMR/CPOE system implementation in a hospital based outpatient cancer center within three treatment sites and with sixteen physicians. Methods: A retrospective chart review was conducted on 32 randomly selected patients to date, who received one of the following regimens: FOLFOX, carboplatin-paclitaxel, CHOP-rituximab, or AC between 1999 and 2006. Charts were case matched with physician and regimen to compare documentation completeness. Completeness scores were assigned to each chart based on the number of documented data points found out of the 33 data points assessed. A user satisfaction survey of the paper chart and EMR/CPOE system was conducted among the physicians (n=16), nurses (n=43), and pharmacists (n=8) who worked with both systems. Results: The mean percentage of identified data points successfully found in the EMR/CPOE charts was 94% vs. 68% in the paper charts (p&lt;0.001). Regimen complexity did not alter the number of data points found. The survey response rate was 64% and the results showed that satisfaction was statistically significant in favor of the EMR/CPOE system. The time required to find the data points will be assessed by having a physician, nurse, and pharmacist review the same charts. Data on 112 charts will be presented. Conclusions: Using EMR/CPOE systems improves completeness of medical record and chemotherapy order documentation and improves user satisfaction with the medical record system. No significant financial relationships to disclose.
Prognostic Value of 25-hydroxyvitamin D3 Levels at Diagnosis and During Follow-up in Melanoma Patients
Authors: Philippe Saiag, Philippe Aegerter, Dominique Vitoux, Celeste Lebbé, Pierre Wolkenstein, Nicolas Dupin, Vincent Descamps, Selim Aractingi, Elisa Funck-Brentano, Philippe Autier, Miruna Dragomir, Mathieu Boniol
Journal: JNCI Journal of the National Cancer Institute (2015)

Background:A low 25-hydroxyvitamin D3 (25(OH)D3) serum concentration at melanoma diagnosis might be associated with worse survival. We prospectively studied the prognostic value of 25(OH)D3 at diagnosis and during follow-up.
Association between ECOG PS, age, and components of the Comprehensive Geriatric Assessment (CGA) in an elderly colorectal cancer (CRC) cohort
Authors: B. N. Polite, K. A. Bylow, J. Hemmerich, C. Martens, E. Karr, C. Rosenbaum, C. Holmstrom, H. L. Kindler, W. Dale
Journal: Journal of Clinical Oncology (2009)

e20603 Background: 75% of CRC patients (pts) are age 65 and older. The ability of ECOG PS and age to predict underlying frailty in older pts has been questioned. This prospective multi-center observational study explores the association between EGOG PS, age and a comprehensive geriatric assessment (CGA) in older CRC pts. Methods: CRC pts aged 65 and older who were eligible for chemotherapy based on disease characteristics are being prospectively enrolled. ECOG PS and CGA measures, including functional status, cognition, comorbidity, and affect, were obtained prior to initiation of chemotherapy using validated, standardized measures. Results: 35 elderly CRC pts enrolled between March 2006 and December 2008. Age: 65–69 46%, 70–74 23%, 75–79 11%, &gt;80 20%; gender: female 65%; race: Caucasian 52%, African-American 46%; stage IV disease: 80%. Baseline ECOG PS: 0 60%, 1 32%, 2 8%. Age did not correlate with any components of the CGA except for dependence in any ADLs (rho 0.4, p=0.03). Associations between the components of the CGA and ECOG PS are shown in the table . Conclusions: Neither biologic age nor ECOG PS were robust proxies for rigorously measured functional status in this elderly CRC cohort. This was especially true for the ECOG 0 and 1 pts where, for example, 80% of the ECOG 0 pts had impaired performance on the Short Physical Performance Battery. Work on this expanding cohort is ongoing to determine correlations with these assessments and the ability to tolerate and complete prescribed chemotherapy regimens. If predictive, the CGA could help better target established geriatric interventions to those elderly pts at greatest risk regardless of their age or performance status. [Table: see text] No significant financial relationships to disclose.
Multimodal therapy for the treatment of fatigue in patients with prostate cancer receiving androgen deprivation therapy and radiation.
Authors: Sriram Yennurajalingam, Cindy Carmack, Karen Basen-Engquist, James M. Reuben, Eduardo Bruera
Journal: Journal of Clinical Oncology (2013)

TPS9650 Background: Cancer-related fatigue (CRF) is the most frequently reported symptom associated with cancer and its treatment. Unfortunately, there are limited treatment options to alleviate this distressing symptom. Preliminary data suggest that the combination of exercise, cognitive behavioral therapy (CBT), and methylphenidate (that is, multimodality therapy [MMT]) can play an important role in reducing CRF. The project’s objective is to explore the effects and safety of this MMT on CRF in prostate cancer patients scheduled to receive radiotherapy with androgen deprivation therapy. We hypothesizethat the MMT is capable of reducing CRF as measured by the FACIT-F subscale in prostate cancer patients scheduled to receive radiotherapy. Specific Aims:(1) Our primary aim is to obtain preliminary estimates of the effects of various treatments (exercise, CBT, and methylphenidate) and their combinations in reducing CRF in prostate cancer patients receiving radiotherapy, as measured by the change in patients’ FACIT-F subscale scores taken at baseline and on day 57 and the secondary objective is to determine the effects of the treatments and their combinations on anxiety and depressed mood (both measured by the Hospital Anxiety Depression Scale [HADS]); on physical activity and function (measured by an accelerometer and a handgrip dynamometer, respectively); on levels of inflammatory cytokines (IL-1β, IL-6, TNF-α, and IL-10) in serum and induced monocytes, before and after treatment Methods: For this study, we will use a randomized factorial design to assess 3 treatments (exercise, CBT, and methylphenidate) and their placebos in 8 replications. A total of 32 patients will receive each primary treatment and 32 will not. Patients will be studied for a 57-day period, during which they are scheduled undergo daily radiation treatments with androgen deprivation therapy. Fatigue, anxiety and depressed mood, and inflammatory cytokines will be determined at baseline and at 3 subsequent post-intervention assessments. After successful initiation so far 19/64 patients were enrolled. Accrual continues. Clinical trial information: NCT01410942.
Meta-analysis of sentinel lymph node biopsy following preoperative chemotherapy in patients with operable breast cancer
Authors: Y. Xing, M. Ding, D. Cox, M. I. Ross, K. K. Hunt, J. N. Cormier
Journal: Journal of Clinical Oncology (2004)

561 Background: Preoperative chemotherapy is being utilized more frequently in patients with early-stage breast cancer. The utility of sentinel lymph node biopsy (SNB) following preoperative chemotherapy is yet to be determined. Methods: A systematic review was conducted through sensitive electronic searches of MEDLINE, Cancerlit, ASCO Proceedings and the Cochrane Collaborative Research Database. Completion axillary lymph node dissection was an inclusion criteria for the analysis. Diagnostic test characteristics were calculated based on pooled data. A meta-analysis was performed using weighted average to calculate the sensitivity of SNB and associated 95% confidence intervals (95% CI). A summary receiver operating characteristic curve (SROC) was constructed using S-Plus robust resistant regression methods to assess test performance. Results: Twelve studies were identified; 11 reported favorable results. The sentinel lymph node was successfully identified in 84% to 98% of patients. The range for reported false negative (FN) rate was 0–20%. The specificity (true negative rate) was reported as 100% in all studies. The identification rate (IR) in studies which utilized combination dye and radioisotope techniques for SNB was higher than in studies using non-standardized (dye or isotope) approaches (91% vs 86%). Pooling of data resulted in an overall IR of 87% with a sensitivity (true positive (TP)/ TP+FN), positive predictive value and overall accuracy of 90%, 100% and 95.2%, respectively. The adjusted parameters revealed a global sensitivity of 89% (95% CI, 0.86–0.93). The area under the SROC curve was 0.98 indicating that SNB following preoperative chemotherapy has outstanding discrimination. Conclusions: The published literature supports the use of SNB for assessment of the axilla in patients with clinically node negative disease following preoperative chemotherapy. Both dye and radioisotope methods should be used to maximize the IR. Meta-analysis demonstrates that the sensitivity of SNB in this clinical scenario is similar to that of patients who have not received preoperative chemotherapy. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration British Journal of Surgery Research Bursaries
Phase I-II trial of imatinib (IM) and low-dose doxorubicin (DX) in patients (pts) with advanced gastrointestinal stromal tumors (GIST), refractory to high-dose IM: A GEIS Study
Authors: A. Poveda, J. Maurel, R. Cubedo, A. Casado, J. Ayuso, D. Fuster, J. Martinez-Trufero, A. Lopez-Pousa, J. Martin, X. Garcia del Muro
Journal: Journal of Clinical Oncology (2008)

10520 Background: In Ewing sarcoma cell lines expressing KIT, the addition of DX to IM increase apoptosis, compared to IM or DX alone. Based on ''in vitro" data, we conducted a phase I-II trial of DX with IM in pts with GIST refractory to high- dose IM therapy. Methods: Pts with metastatic TKI-resistant GIST to IM at 400 mg p.o.bid, were eligible for a multicenter study and received IM (400 mg p.o.qd) concomitantly with DX 15–20 mg/m2/weekly per 4 cycles (monthly cycles), followed by IM (400 mg p.o.qd) maintenance in non-progressive pts. Spiral computed tomography (CT) and positron emission tomography with F18-fluorodeoxyglucose (FDG- PET) were done basally and at 2 months therapy for response evaluation. CT were repeated at four and six months and every 3 months thereafter, until disease progression. Results: 26 pts with progressive GIST have been entered at 2 dose levels (15 mg/m2/w DX; n=3) and (20 mg/m2/w DX; n=23). There were 24 male, 2 female, with a median age of 57 years (26–80). 18 of 26 pts (69%) were strictly refractory (progressive disease at 3 month) to IM 400 mg p.o bid. 23 pts are currently evaluable. A total of 70 cycles (range 2–4) of therapy were administered. Treatment was well tolerated. Most frequent adverse events include: alopecia, anorexia, edema and mucositis. Grade 3–4 toxicity occurred in <5% of cycles. Two of 23 pts (9%) had partial responses by RECIST criteria and 10 (43%) had stable disease ≥16 weeks. Median progression-free survival was 84 days (95%CI 56–112). Conclusions: Low-dose chemo-biotherapy combination showed promising activity in heavily pretreated GIST pts, and appears as a reasonable and safe option for pts failing to high-dose IM therapy. No significant financial relationships to disclose.
False-positive results of an iodine-131 whole-body scan caused by an ectopic kidney.
Authors: M Attard, P Marozzi, L Gambino, F Janní, P Salice, U Ficola, D Giuffrida
Journal: Clinical Nuclear Medicine (2001)

ATTARD, MARCO M.D.,*; MAROZZI, PAOLA M.D.,†; GAMBINO, LEONARDO M.D.,*; JANNÍ, FRANCESCO M.D.,*; SALICE, PLACIDO M.D.,‡; FICOLA, UMBERTO M.D.†; GIUFFRIDA, DARIO M.D.‡ Author Information
Outpatient stem cell transplantation for multiple myeloma
Authors: A. Ghavamzadeh, K. Alimoghaddam, A. Karimi, A. Manookian, M. Asadi, R. Maheri, A. Shamshiri
Journal: Journal of Clinical Oncology (2009)

e19553 Background: The aim of this study was to explore the feasibility and safety of performing aoutologous stem cell transplantation (ASCT) on an outpatient basis. Methods: 142 patients with multiple myeloma (MM) in complete remission (CR) or partial remission (PR) received ASCT on an outpatient or inpatient basis. In the inpatient group 77 patients and in outpatient group 65 patients received 200 or 140 mg/m 2 melphalan as conditioning regimen respectively. In outpatient group all the patients were programmed to go home the day after ASCT and to be re-hospitalized in the case of febrile neutropenia or other sever toxicities. We used caregiver, general physician, staff nurse as an outpatient and visit team and also unequipped routine house of the patients during neutropenia. Results: Median age was 50.2 years (ranged 27–68) with 70% male. Median hospital stay were 25 days in inpatient and. 4.8 days in outpatient respectively (p&lt;0.01). There were not significant differences between these groups in aphresis days, granulocyte colony stimulating factor requirement for mobilization and mononuclear cell, There were also significant reduction (p&lt;0.001) in parenteral antibiotic, blood product requirement and need for total parenteral nutrition. The most frequent causes of re-admission (outpatient group) were febrile neutropenia and sever mucositis need TPN. 2 years overall survival rate was 98.2% (SE=2%) in inpatient groups and 86.6% (SE=5.7) in outpatient groups.We did not have any death in first month after transplantatio in outpatient group. Conclusions: We describe an outpatient program based on management of the patient in his/her house during aplastic phase. Our results clearly indicate that such a procedure is feasible and safe in a patient population with a caregiver. No significant financial relationships to disclose.
Induction of Noxa Via Generation of Reactive Oxygen Species Plays a Key Role in Induction of CLL Cell Apoptosis by Two Novel p53-Independent Cytotoxic Agents.
Authors: Andrew Steele, Archibald G Prentice, Anastasios Chanalaris, A. Victor Hoffbrand, Kate Cwynarski, Ranmohan Wickremasinghe
Journal: Blood (2009)
Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: A phase II trial
Authors: T. Ng, T. DiPetrillo, M. Suntharalingam, J. Fontaine, B. McNulty, P. Akerman, W. Chen, M. N. Horiba, W. Burrows, H. Safran
Journal: Journal of Clinical Oncology (2009)

e15542 Background: Paclitaxel poliglumex (PPX) is a drug conjugate that links paclitaxel to poly-L-glutamic acid thereby increasing its radiation enhancement factor to 4.0 to 8.0 compared to 1.5–2.0 for paclitaxel. The Brown University Oncology Group previously performed a phase I study establishing the dose of single agent PPX with radiation, and the combination of PPX, cisplatin and radiation for esophagogastric cancer. A phase II study was therefore initiated to evaluate the pathologic response rate of neoadjuvant PPX, cisplatin and radiation for patients with esophageal cancer. Methods: Eligible patients had pathologically confirmed adenocarcinoma or squamous cell carcinoma of the esophagus or GE junction with no evidence of distant metastasis. Celiac nodal disease was allowed. Patients received weekly PPX 50mg/m 2 and cisplatin 25mg/m 2 for 6 weeks with concurrent with 50.4Gy of radiation. Six to eight weeks after completion of chemoradiotherapy, patients underwent surgical resection. Results: Twenty-three eligible patients have been enrolled. The median age is 63 years. Grade 3/4 treatment related toxicities in the first 15 patients include dehydration (n=5), anorexia (n=5), esophagitis/dysphagia (n=4), electrolyte abnormalities (n=3), nausea (n=2), hypersensitivity (n=2), weight loss (n=1), and anemia (n=1). One patient developed carcinomatous meningitis during treatment. Five of the first 11 patients (45%) undergoing resection had a pathologic complete response. Conclusions: This preliminary data suggests that PPX may provide enhanced radiosensitization as compared to standard paclitaxel, consistent with the preclinical data of PPX and radiation. No significant financial relationships to disclose.
MYCN gene amplification and DNA ploidy in peripheral neuroblastic tumors
Authors: D. M. Abdalla, M. A. Hamza, A. E. Kandil, L. K. Younes, A. F. Sorrour
Journal: Journal of Clinical Oncology (2009)

e22123 Background: Neuroblastoma is a neuroblastic tumor of the primordial crest cells which are precursors of the sympathetic nervous system and is the most common extracranial solid tumor of childhood comprising between 8 and 10% of all childhood cancers. Neuroblastoma is characterized by a diverse clinical and biological behavior The spectrum of clinical behavior suggests that genetic, biological and morphological features may be useful markers to stratify children with this disease for the most appropriate management Fluorescence in situ hybridization (FISH) is considered the best approach for detection of MYCN amplification because it can detect small copy number gains and copy number heterogeneity among tumor cells. Also, it can determine the source of amplified MYCN signal, whether extrachromosomal double minutes, expanded intrachromosomal region or chromosome 2 aneuploidy. Methods: 30 cases of peripheral neuroblastic tumors were analysed for MYCN oncogene copy number and DNA ploidy using FISH. The 30 cases were divided into: 25 cases of neuroblastoma, 2 cases of ganglioneuroblastoma intermixed, and 3 cases of ganglioneuroma. Results: MYCN oncogene was amplified in 8 out of 30 cases (27.5%). 3 cases showed double minutes, 3 cases showed homogenously staining regions and 2 cases showed both forms of amplification. As regard DNA ploidy, 18 cases were diploid and 12 cases were hyperdiploid. MYCN oncogene amplification was significantly correlated with unfavorable histology, advanced tumor stage increased recurrence and poor survival. Also ploidy was associated with increased recurrence and reduced survival. And so, MYCN oncogene amplification and DNA ploidy were poor prognostic markers and it is recommended that assessment of these factors should be routine in the management of any case of neuroblastoma. Conclusions: 1) MYCN gene amplificahion and DNA plidy are poor prognostic markers 2) They should be measured in every case of peripheral neuroblastic tumors. 3) FISH should be used in the detechion of MYCN oncogene amplification and DNA ploidy No significant financial relationships to disclose.
Abstract 14369: Presence of a Transvalvular Pacemaker Increases the Risk of Postoperative Regurgitation Following Tricuspid Valve Surgery
Authors: Emmanuel Moss, Amine Mazine, Marilyn Durivage, Guillaum Marquis-Gravel, Denis Bouchard, Louis P Perrault, Pierre Page, Philippe Demers, Hugues Jeanmart, Nancy C Poirier, Michel Carrier, Raymond Cartier, Yves Hebert, Michel Pellerin
Journal: Circulation (2012)

Background: The impact of a transvalvular pacemaker lead on the progression of tricuspid regurgitation (TR) following tricuspid valve (TV) surgery has not been clearly demonstrated. The aim of this...